HER3 expression can also mediate resistance to targeted therapy (e.g., resistance to EGFR-targeted therapies in lung cancer, via maintenance of HER3-mediated activation of PI3K/AKT signaling53,54. This evidence concerns the gene ERBB3 and lung carcinoma.